Search

Your search keyword '"Eller, Kathrin"' showing total 481 results

Search Constraints

Start Over You searched for: Author "Eller, Kathrin" Remove constraint Author: "Eller, Kathrin"
481 results on '"Eller, Kathrin"'

Search Results

3. Homocysteine contributes to atherogenic transformation of the aorta in rabbits in the absence of hypercholesterolemia

10. Diagnose und Therapie der Granulomatose mit Polyangiitis und mikroskopische Polyangiitis – 2023: Konsens-Empfehlungen der Österreichischen Gesellschaften für Nephrologie (ÖGN) & Rheumatologie (ÖGR)

13. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

14. A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT

16. Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange

17. Pre-Transplant Frequencies of FoxP3+CD25+ in CD3+CD8+ T Cells as Potential Predictors for CMV in CMV-Intermediate Risk Kidney Transplant Recipients

18. #2084 Biologic effect evaluation of de novo long-term release tacrolimus on metabolizer phenotype and T cell composition after kidney transplantation

22. Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design

24. International consensus on post-transplantation diabetes mellitus

26. Immunologically relevant aspects of the new COVID-19 vaccines—an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper

27. Rituximab in Membranous Nephropathy

28. Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.

29. Pre-Transplant Frequencies of FoxP3+CD25+ in CD3+CD8+ T Cells as Potential Predictors for CMV in CMV-Intermediate Risk Kidney Transplant Recipients.

30. Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation

31. Changes in cardiac troponins during hemodialysis depend on hemodialysis membrane and modality: a randomized crossover trial

33. MicroRNA-142-3p improves vascular relaxation in uremia

34. Changes in cardiac troponins during hemodialysis depend on hemodialysis membrane and modality: a randomized crossover trial.

35. Homocysteine contributes to atherogenic transformation of the aorta in rabbits in the absence of hypercholesterolemia

36. COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases

37. Reduced COVID-19 morbidity and mortality in hemodialysis patients across the various Omicron sublineages—A retrospective analysis

38. Influence of Early Postoperative Basal Insulin Treatment and Post-Transplant Diabetes Mellitus Risk on Health-Related Quality of Life in Kidney Transplant Recipients—An Analysis of Data From a Randomized Controlled Trial

39. Diagnosis and therapy of membranous nephropathy—2023

40. Diagnosis and treatment of focal-segmental glomerulosclerosis—2023

41. #4574 ATYPICAL CHEMOKINE RECEPTOR 4 IS EXPRESSED IN GLOMERULAR PARIETAL EPITHELIAL CELLS AND MITIGATES THE SEVERITY OF EXPERIMENTAL GLOMERULONEPHRITIS

42. COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases

43. A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT

44. Hospitalizations, emergency room visits and causes of death in 198 patients with permanent hypoparathyroidism: a retrospective Austrian study (2005–2022)

45. A Multicentre, Patient- and Assessor-blinded, Non-inferiority, Randomised and Controlled Phase Ii Trial to Compare Standard and Torque Teno Virus-guided Immunosuppression in Kidney Transplant Recipients in the First Year After Transplantation: Ttv Guide It

46. Management of Immune Thrombotic Thrombocytopenic Purpura Without Therapeutic Plasma Exchange

47. Additional file 6 of A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT

48. Additional file 2 of A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT

49. Additional file 3 of A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT

50. Additional file 8 of A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT

Catalog

Books, media, physical & digital resources